Allison June Kaeding MD

PubMed

• 5 citations
  Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
  Anilkumar Gopalakrishnapillai, Colin Correnti, Kristina Pilat, Ida Lin, Man Kid Chan
  Cancers. 2021-11-26
• 20 citations
  Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.
  Allison Kaeding, Sonali P. Barwe, Anilkumar Gopalakrishnapillai, Rhonda E. Ries, Todd A. Alonzo
  Blood Advances. 2021-05-11
• 114 citations
  The natural history of soy allergy
  Jessica H. Savage, Allison J. Kaeding, Elizabeth C. Matsui, Robert A. Wood
  The Journal of Allergy and Clinical Immunology. 2009-02-01

Abstracts/Posters

• In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia
  Allison Kaeding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity
  Allison Kaeding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies
  Allison Kaeding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018